Weighing in on autoimmune disease: Big data tip the scale

Modern medicine keeps unraveling new ways to investigate autoimmunity, leading to the production of boundless amounts of genetic, cellular and imaging data. Although the precision with which this information can define the etiology and mechanisms of a particular autoimmune disease is encouraging, much work lies ahead until all the knowledge acquired can be translated into the clinic. In 'Bedside to Bench', Calliope A. Dendrou, John I. Bell and Lars Fugger discuss the promises and limitations of genome-wide and next-generation genetic studies to provide further understanding of mechanisms driving autoimmune disorders and the role of experimental medicine in the new era of integrative clinical practice and personalized medicine. In 'Bench to Bedside', Lawrence Steinman argues the concept of a 'hub and spoke' pattern of T cell activation and organ targeting in multiple sclerosis, inflammatory bowel disease and type 1 diabetes. This paradigm suggests new ways to develop drugs to keep autoreactive T cells in the organ where activation occurs and preclude them from reaching the target organ and cause disease.

[1]  K. Fujihara,et al.  Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. , 2012, Brain : a journal of neurology.

[2]  P. Gregersen,et al.  Prevention of autoimmune rheumatic disease: state of the art and future perspectives , 2010, Annals of the rheumatic diseases.

[3]  Vineet Bafna,et al.  Exome Sequencing Can Improve Diagnosis and Alter Patient Management , 2012, Science Translational Medicine.

[4]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[5]  H. Zeidler,et al.  Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial , 2002, The Lancet.

[6]  James T. Elder,et al.  Identification of fifteen new psoriasis susceptibility loci highlights the role of innate immunity , 2012, Nature Genetics.

[7]  Subhashis Banerjee,et al.  Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. , 2012, The New England journal of medicine.

[8]  K. Flaherty,et al.  RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. , 2012, The New England journal of medicine.

[9]  B. Strober,et al.  Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. , 2010, The New England journal of medicine.

[10]  Calliope A. Dendrou,et al.  TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis , 2012, Nature.